News & Updates
Showing Multidisciplinary articles
Showing

T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
A real-world propensity score-matched study in Hong Kong finds that, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D) patients is associated with lower risk of incident atrial fibrillation (AF), stroke/transient ischaemic attack (TIA), and cardiovascular (CV) and all-cause mortality.
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
05 Mar 2022
Physically active women less reliant on pain meds for headache
A cross-sectional study by the German Migraine and Headache Society reports a lower use of analgesics among physically active women prone to headaches vs physically inactive counterparts.
Physically active women less reliant on pain meds for headache
05 Mar 2022
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
04 Mar 2022
Empiric antibiotic use confers no therapeutic benefit in COVID-19 pneumonia
The use of empiric antibiotic therapy appears to prevent neither deterioration nor death among patients with COVID-19 pneumonia, as shown in a Singapore study.
Empiric antibiotic use confers no therapeutic benefit in COVID-19 pneumonia
04 Mar 2022
Ustekinumab safe, effective in Asians with severe plaque psoriasis
Ustekinumab, a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, demonstrates effectiveness and safety in the treatment of multiethnic Asian patients with moderate to severe plaque psoriasis, according to a Singapore study.




